SCHEMBL14716705

SCHEMBL14716705

CC(=O)Nc1nc2nc(N=NC(=O)c3ccc(C)cc3)[nH]c2c(=O)[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 6/20 0.53
FGFR2 P21802 6/20 0.53
FGFR3 P22607 3/20 0.53
GDA Q9Y2T3 1/20 0.46
TDP1 Q9NUW8 2/20 0.45
GAA P10253 2/20 0.42
KDM4E B2RXH2 1/20 0.42
POLB P06746 1/20 0.38
ALOX15 P16050 1/20 0.38
ALDH1A1 P00352 1/20 0.38
ADORA3 P0DMS8 2/20 0.36
NPC1 O15118 1/20 0.35
PKM P14618 1/20 0.35
OPRK1 P41145 1/20 0.35
RAB9A P51151 1/20 0.35
KLF5 Q13887 1/20 0.35
LMNA P02545 1/20 0.34
MGAM O43451 1/20 0.34
SI P14410 1/20 0.34
MGAM2 Q2M2H8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14716707 0.83 TDP1 (0.46) FGFR1FGFR2FGFR3GDATDP1
SCHEMBL14716410 0.82 FGFR1 (0.46) FGFR1FGFR2
SCHEMBL14716735 0.75 FGFR1 (0.53) FGFR1FGFR2FGFR3GDATDP1
SCHEMBL14716598 0.75 FGFR1 (0.51) FGFR1FGFR2FGFR3GDATDP1
SCHEMBL16513137 0.71 GDA (0.64) FGFR1FGFR2FGFR3GDATDP1
SCHEMBL14716392 0.70 FGFR1 (0.46) FGFR1FGFR2FGFR3GDATDP1
SCHEMBL12320829 0.69 TDP1 (0.49) FGFR1FGFR2FGFR3GDATDP1
SCHEMBL14716409 0.68 KDM4E (0.39) GAAKDM4EPOLBALDH1A1NPC1
SCHEMBL14716412 0.68 KDM4E (0.39) GAAKDM4EPOLBALDH1A1NPC1
SCHEMBL2435283 0.68 FGFR1 (0.59) FGFR1FGFR2FGFR3GDATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458515-B2 RNA including nucleoside compound, method for regulating amount of protein produced from the RNA, and nucleoside compound RIKEN (JP) 2016-10-04 US disclosed
US-20130052710-A1 RNA INCLUDING NUCLEOSIDE COMPOUND, METHOD FOR REGULATING AMOUNT OF PROTEIN PRODUCED FROM THE RNA, AND NUCLEOSIDE COMPOUND RIKEN (JP) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130052710-A1 RNA INCLUDING NUCLEOSIDE COMPOUND, METHOD FOR REGULATING AMOUNT OF PROTEIN PRODUCED FROM THE RNA, AND NUCLEOSIDE COMPOUND RNMT, NSUN2, RNGTT FGFR1 4325/4885FGFR2 4803/4885FGFR3 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.